Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma

Respiratory Medicine

Volumn 97, Issue 12, 2003, Pages 1313-1319

  Yurdakul, Ahmet Selim ^a   Taci, Nevin ^a   Eren, Ayşeguül ^a   Şipit, Tugğrul ^a  

^a Thoracic Surgery Training and Research Hospital   (Turkey)

Author keywords

Asthma; Budesonide; Montelukast; Theophylline; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; TERBUTALINE; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SUSTAINED DRUG RELEASE; SYMPTOMATOLOGY;

EID: 0346901080     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2003.07.007     Document Type: Article

References (22)

1. National Institutes of Health. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. National Heart, Lung, and Blood Institute, 2002.
2. Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999;353:57-62.
3. Barnes PJ, Pauwels RA. Theophylline in the management of asthma: time for reappraisal? Eur Respir J 1994;7:579-91.
4. Kidney J, Dominguez M, Taylor PM, Rose M, Chung KF, Barnes PJ. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. Am J Respir Crit Care Med 1995;151:1907-14.
5. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 1994;343:1006-8.
6. Lim S, Tomita K, Carramori G, et al. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 2001;164:273-6.
7. Herjavecz I, Blomqwist P, Serrano A. Efficacy of once- and twice-daily administration of budesonide via Turbuhaler® as initial therapy in patients with mild persistent asthma. Respir Med 1999;93:230-5.
8. Jones AH, Langdon CG, Lee PS, et al. Pulmicort® turbo-haler® once daily as initial prophylactic therapy for asthma. Respir Med 1994;88:293-9.
9. Molimard M, Bourcereau J, Gros VL, Bourdeix I, Leynadier F, Duroux P. Comparison between formoterol 12 μg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir Med 2001;95:64-70.
10. National Heart, Lung, and Blood Institute. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. Publication No. 97-4051, National Institutes of Health, Bethesda, MD, 1997.
11. Dahl R, Larsen BB, Venge P. Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 2002;96:432-8.
12. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461-8.
13. Altman LC, Munk Z, Seltzer J, et al. A placebo-contolled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998;102:50-6.
14. Dempsey OJ, Kennedy G, Lipworth BJ. Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002;109:68-74.
15. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997;337:1412-8.
16. Rivington RN, Boulet L-P, Coté J, et al. Efficacy of Uniphyl®, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995;151:325-32.
17. Edwards TB, Dockhorn RJ, Wagner DE, et al. Efficacy of once daily extended-release theophylline in decreasing the use of inhaled β2-agonists in stable, mild-to-modorate asthma patients. Ann Allergy 1995;75:409-16.
18. Chisholm SL, Dekker FW, Neven AK, Petri H. Once-daily budenosid in mild asthma. Respir Med 1998;92:421-5.
19. Mintz S, Alexander M, Li JH, Mayer PV. Once-daily administration of budesonide Turbohaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma. J Asthma 2002;39:203-10.
20. Gagnon M, Cote J, Milot J, Turcotte H, Boulet LP. Comparative safety and efficacy of single twice daily administration of inhaled beclomethasone in moderate asthma. Chest 1994;105:1732-7.
21. Brattsand R. Pharmacology of budesonide: factors determining local efficacy. Pulmicort Turbohaler® Once Daily. International Workshop Report, 1999. p. 15-9.
22. Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994;331:700-5.